USANA Health Sciences, Inc. (USNA): Price and Financial Metrics


USANA Health Sciences, Inc. (USNA): $98.46

3.86 (+4.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

USNA POWR Grades


  • Quality is the dimension where USNA ranks best; there it ranks ahead of 99.89% of US stocks.
  • USNA's strongest trending metric is Stability; it's been moving up over the last 199 days.
  • USNA's current lowest rank is in the Momentum metric (where it is better than 50.96% of US stocks).

USNA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for USNA is 2.57 -- better than 81.19% of US stocks.
  • Of note is the ratio of Usana Health Sciences Inc's sales and general administrative expense to its total operating expenses; just 18.42% of US stocks have a lower such ratio.
  • For USNA, its debt to operating expenses ratio is greater than that reported by just 0.32% of US equities we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Usana Health Sciences Inc are JOUT, WIRE, SNDR, SCSC, and DWSN.
  • Visit USNA's SEC page to see the company's official filings. To visit the company's web site, go to www.usana.com.

USNA Stock Price Chart Interactive Chart >

Price chart for USNA

USNA Price/Volume Stats

Current price $98.46 52-week high $102.96
Prev. close $94.60 52-week low $68.30
Day low $94.03 Volume 133,300
Day high $98.70 Avg. volume 116,929
50-day MA $97.86 Dividend yield N/A
200-day MA $84.45 Market Cap 2.03B

USANA Health Sciences, Inc. (USNA) Company Bio


USANA Health Sciences develops and manufactures nutritional supplements, healthy foods and personal care products. The company was founded in 1992 and is based in Salt Lake City, Utah.

USNA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$98.46$60.21 -36%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Usana Health Sciences Inc. To summarize, we found that Usana Health Sciences Inc ranked in the 43th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 36%. In terms of the factors that were most noteworthy in this DCF analysis for USNA, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 100. Notably, its equity weight is greater than 98.65% of US equities in the Consumer Defensive sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 0% of the free cash flow producing stocks we're observing.
  • USNA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 60.97% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-38%
1%-37%
2%-36%
3%-36%
4%-35%
5%-34%

For other companies in the Consumer Defensive that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as USNA, try CLX, TAP, CCEP, MENB, and INGR.


USNA Latest News Stream


Event/Time News Detail
Loading, please wait...

USNA Latest Social Stream


Loading social stream, please wait...

View Full USNA Social Stream

Latest USNA News From Around the Web

Below are the latest news stories about Usana Health Sciences Inc that investors may wish to consider to help them evaluate USNA as an investment opportunity.

USANA Health Sciences (USNA) Q1 Earnings Lag Estimates

USANA Health (USNA) delivered earnings and revenue surprises of -7.64% and 2.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | April 27, 2021

USANA Health Sciences Reports First Quarter Results

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 3, 2021.

Yahoo | April 27, 2021

Direct Selling News honors USANA and its CEO with three major awards

USANA Health Sciences, a global leader in nutrition, recently received three major awards from the direct selling industry's top publication, Direct Selling News (DSN). USANA CEO Kevin Guest earned the coveted Bravo Leadership award for his success as a leader both of the company and on behalf of the entire direct selling industry. USANA was also named to DSN's Best Places to Work and Global 100 lists. It's the fourth time USANA has been recognized as one of the Best Places to Work in direct selling, while also moving up from 16 to 14—its highest ever ranking—on the Global 100 list of top revenue generating direct sales companies.

Yahoo | April 26, 2021

Do USANA Health Sciences's (NYSE:USNA) Earnings Warrant Your Attention?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Yahoo | April 9, 2021

USANA Schedules First Quarter Earnings Release and Conference Call

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter results will be released after the close of market Tuesday, April 27, 2021. Shortly following the issuance of the Company’s earnings release, the Company will post a "Management Commentary, Results and Outlook" document on the Company’s website (http://ir.usana.com) under the "Investor Relations" section of the site. The following morning at 11:00 a.m. Eastern Time, USANA will hold a conference call to discuss this announcement with analysts and institutional investors.

Yahoo | April 8, 2021

Read More 'USNA' Stories Here

USNA Price Returns

1-mo -1.38%
3-mo 16.94%
6-mo 27.13%
1-year 13.56%
3-year -11.81%
5-year 58.08%
YTD 27.70%
2020 -1.85%
2019 -33.28%
2018 58.99%
2017 21.00%
2016 -4.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8693 seconds.